SINGAPORE, 14 APRIL 2022: Us2.ai, the Singapore-based medtech developers of FDA- cleared AI software that, for the first time ever, fully automates a complete echocardiography (heart ultrasound) report, today announced...
Eric Linsley offers perspective on personalized medicine’s development
News | 03. 06. 2012
Eric Linsley offered his perspective on personalized medicine’s development during a symposium for PMC's recent report, The Case for Personalized Medicine. Linsley joined Jennie Hunter-Cevera, Ph.D., Executive Vice President, RTI International; Jonathan Roy, Senior Director and Head of Commercial Diagnostics for GlaxoSmithKline; Amy Abernethy, M.D., Director, Cancer Care Research Program at Duke University and David King, CEO of the Laboratory Corporation of America.
The Personalized Medicine Coalition latest newsletter summarizes these perspectives.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.